Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8671879 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL1776767 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL7565739 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL6788287 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL12281867 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL25083758 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL6788279 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL12237522 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL19861473 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL16215761 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023011597-A1 | LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS | Hepagene Therapeutics (HK) Limited (CN) | 2023-02-09 | — | — | WO | disclosed |
| US-8658112-B2 | Microfluidic chip capable of synthesizing radioactively labeled molecules on a scale suitable for human imaging with positron emission tomography | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120101268-A1 | Microfluidic Chip Capable of Synthesizing Radioactively Labeled Molecules on a Scale Suitable for Human Imaging With Positron Emission Tomography | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| EP-1940543-B1 | MICROFLUIDIC CHIP CAPABLE OF SYNTHESIZING RADIOACTIVELY LABELED MOLECULES ON A SCALE SUITABLE FOR HUMAN IMAGING WITH POSITRON EMISSION TOMOGRAPHY | SIEMENS MEDICAL SOLUTIONS (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7943584-B2 | Medicinal composition containing diabetes remedy | SANKYO COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1589023-B1 | OLIGOSACCHARIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7632930-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20080194495-A1 | Oligosaccharide Derivative | HONDA TAKESHI | 2008-08-14 | — | — | US | disclosed |
| EP-1940543-A2 | MICROFLUIDIC CHIP CAPABLE OF SYNTHESIZING RADIOACTIVELY LABELED MOLECULES ON A SCALE SUITABLE FOR HUMAN IMAGING WITH POSITRON EMISSION TOMOGRAPHY | Siemens Medical Solutions USA, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| US-7361744-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | SANKYO COMPANY, LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20070217963-A1 | Microfluidic chip capable of synthesizing radioactively labeled molecules on a scale suitable for human imaging with positron emission tomography | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2007-09-20 | — | — | US | disclosed |
| EP-1792620-A1 | MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY | Sankyo Company, Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007041486-A2 | MICROFLUIDIC CHIP FOR SYNTHESIZING RADIOACTIVELY LABELED MOLECULES SUITABLE FOR HUMAN IMAGING WITH POSITRON EMISSION TOMOGRAPHY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20060025350-A1 | Oligosaccharide derivative | SANKYO COMPANY, LIMITED (JP) | 2006-02-02 | — | — | US | disclosed |
| EP-1589023-A1 | OLIGOSACCHARIDE DERIVATIVE | Sankyo Company, Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-4912204-A | Fluoro-substituted epipodophyllotoxin glucosides | BRISTOL-MYERS COMPANY (US) | 1990-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | DPP4, IAPP, AMY2A | CYP2D6 716/4885THRB 1654/4885HSD17B10 619/4885 |
| US-20060025350-A1 | Oligosaccharide derivative | MAN1B1, FUT6, MAN2A1 | CYP2D6 1546/4885THRB 1449/4885HSD17B10 352/4885 |
| US-20080194495-A1 | Oligosaccharide Derivative | MAN1B1, FUT6, MAN2A1 | CYP2D6 1546/4885THRB 1449/4885HSD17B10 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.